- Home
- AXGN vs DVAX Comparison
AXGN vs DVAX Comparison
Compare AXGN & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXGN
- DVAX
- Stock Information
- Founded
- AXGN N/A
- DVAX 1996
- Country
- AXGN United States
- DVAX United States
- Employees
- AXGN N/A
- DVAX N/A
- Industry
- AXGN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- AXGN Health Care
- DVAX Health Care
- Exchange
- AXGN Nasdaq
- DVAX Nasdaq
- Market Cap
- AXGN 1.2B
- DVAX 1.2B
- IPO Year
- AXGN N/A
- DVAX 2004
- Fundamental
- Price
- AXGN $28.43
- DVAX $11.45
- Analyst Decision
- AXGN Strong Buy
- DVAX Buy
- Analyst Count
- AXGN 7
- DVAX 4
- Target Price
- AXGN $27.71
- DVAX $26.50
- AVG Volume (30 Days)
- AXGN 817.5K
- DVAX 1.9M
- Earning Date
- AXGN 10-29-2025
- DVAX 11-05-2025
- Dividend Yield
- AXGN N/A
- DVAX N/A
- EPS Growth
- AXGN N/A
- DVAX N/A
- EPS
- AXGN N/A
- DVAX N/A
- Revenue
- AXGN $214,709,000.00
- DVAX $330,514,000.00
- Revenue This Year
- AXGN $21.57
- DVAX $23.23
- Revenue Next Year
- AXGN $15.79
- DVAX $16.57
- P/E Ratio
- AXGN N/A
- DVAX N/A
- Revenue Growth
- AXGN 18.72
- DVAX 26.73
- 52 Week Low
- AXGN $9.22
- DVAX $9.20
- 52 Week High
- AXGN $28.99
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- AXGN 81.70
- DVAX 63.72
- Support Level
- AXGN $28.00
- DVAX $11.33
- Resistance Level
- AXGN $28.92
- DVAX $11.58
- Average True Range (ATR)
- AXGN 1.16
- DVAX 0.31
- MACD
- AXGN 0.26
- DVAX 0.02
- Stochastic Oscillator
- AXGN 90.32
- DVAX 87.09
About AXGN Axogen Inc.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.